Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists hunt for blood clues to tame unpredictable swelling attacks

NCT ID NCT04963634

Knowledge-focused Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aimed to find biomarkers (measurable substances in the blood) that could help doctors diagnose bradykinin angioedema and predict how severe attacks might be. The condition causes sudden, unpredictable swelling, and current tests don't work well for all types. Researchers planned to compare blood proteins from patients with the condition to healthy people, but the study was stopped early after enrolling only one participant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1 person

The number who actually took part.

Started

Jan 2022

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with bradykinin angioedema or histamine-mediated angioedema followed in internal medicine department of Lille University Hospital

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Group 1 : Patients with bradykinin angioedema * Patient with biologically proven hereditary angioedema with C1 inhibitor deficiency, * Or a patient with bradykinin angioedema related to a plasminogen or factor XII mutation, * Or patients with bradykinin angioedema related to ACE inhibitors or ARB2, * Or patient with acquired bradykinin angioedema due to C1 inhibitor deficiency, * Age \> or = 18 years with the capacity to understand the requirements of the study and to give a non-opposition * Having a blood collection scheduled as part of routine care * Being insured by social security Group 2 : Patients with histamine-mediated angioedema * Patient with idiopathic histamine angioedema as determined by the referring physician * Age \> or = 18 years with the capacity to understand the requirements of the study and to give a non-opposition * Having a blood collection scheduled as part of routine care * Being insured by social security Exclusion Criteria: * Minors or protected adults, * Pregnant or breastfeeding woman, * Person deprived of liberty, * Person in an emergency situation, * Person having refused or unable to give their non-opposition

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acquired bradykinin angioedema due to C1 inhibitor deficiency are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired angioedema angioedema hereditary angioedema with C1Inh deficiency hereditary angioedema with normal C1Inh renin-angiotensin-aldosterone system-blocker-induced angioedema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Angio edema

Contacts and locations

Locations

  • Hop Claude Huriez Chu Lille

    Lille, 59037, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.